Should I buy or sell Armata Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares. View ARMP analyst ratings or view top-rated stocks .

What is Armata Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Armata Pharmaceuticals' shares. Their ARMP share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 161.2% from the stock's current price. View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts .

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Based on an average daily volume of 18,300 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's stock are sold short. View Armata Pharmaceuticals' Short Interest .

When is Armata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ARMP earnings forecast .

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.55) earnings per share for the quarter. The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.68 million. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative trailing twelve-month return on equity of 280.95%.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV) , Vaxart (VXRT) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , Micron Technology (MU) , Aduro Biotech (ADRO) , Occidental Petroleum (OXY) and Gilead Sciences (GILD) .

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include SeaCrest Wealth Management LLC (0.09%). View institutional ownership trends .

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free ARMP Stock Alerts

$2.68

+0.13 (+5.10%)

(As of 10:37 AM ET)

Compare

Today's Range: $2.50
▼
$2.79
50-Day Range: N/A
52-Week Range: $1.07
▼
$5.26

Volume: 3,804 shs
Average Volume: 17,471 shs
Market Capitalization: $96.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Get Armata Pharmaceuticals alerts:

Armata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 161.2% Upside
$7.00 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.34) to ($1.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of Armata Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Armata Pharmaceuticals has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Armata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Armata Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARMP.

1.9

News and Social Media Coverage

News Sentiment
Armata Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Armata Pharmaceuticals this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.34) to ($1.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Armata Pharmaceuticals is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Armata Pharmaceuticals is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

Click here and I’ll give you all the details.

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

ARMP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARMP Stock News Headlines

April 16, 2024 | americanbankingnews.com

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

March 23, 2024 | finance.yahoo.com

Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth

March 22, 2024 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

March 21, 2024 | finance.yahoo.com

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

March 15, 2024 | finance.yahoo.com

INVA Apr 2024 15.000 call

April 19, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

March 10, 2024 | finance.yahoo.com

INVA Mar 2024 7.500 call

March 6, 2024 | investing.com

Armata secures $35 million to fund phage therapy trials

March 4, 2024 | finance.yahoo.com

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

February 21, 2024 | finance.yahoo.com

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

February 21, 2024 | prnewswire.com

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

February 10, 2024 | investing.com

Armata Pharmaceuticals Inc (ARMP)

February 2, 2024 | morningstar.com

Armata Pharmaceuticals Inc ARMP

November 15, 2023 | markets.businessinsider.com

Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy Rating

November 15, 2023 | finance.yahoo.com

Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates

November 15, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

November 14, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

November 6, 2023 | money.usnews.com

Lexeo Therapeutics Inc.

October 30, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

October 19, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

October 4, 2023 | msn.com

Armata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16

September 28, 2023 | markets.businessinsider.com

Armata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy Recommendation

September 26, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

September 21, 2023 | finance.yahoo.com

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

See More Headlines

Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:ARMP
CUSIP: N/A
CIK: N/A
Web: www.armatapharma.com
Phone: (310) 655-2928
Fax: 310-665-2963
Employees: 66
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +174.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,040,000.00
Net Margins: -1,524.51%
Pretax Margin: -1,524.51%
Return on Equity: -280.95%
Return on Assets: -52.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $4.53 million
Price / Sales: 20.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.89) per share
Price / Book: -2.87

Miscellaneous

Outstanding Shares: 36,150,000
Free Float: 5,242,000
Market Cap: $92.18 million
Optionable: Not Optionable
Beta: 0.85

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Mina Pastagia M.D. (Age 49)
MS, Chief Medical Officer
Comp: $537.6k
Dr. Deborah L. Birx M.D. (Age 67)
CEO & Director
Mr. Richard Rychlik (Age 68)
VP, Corporate Controller & Principal Financial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ARMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Armata Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares.
View ARMP analyst ratings or view top-rated stocks.
What is Armata Pharmaceuticals' stock price target for 2024?: 1 Wall Street analysts have issued 12-month price objectives for Armata Pharmaceuticals' shares. Their ARMP share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts.
Are investors shorting Armata Pharmaceuticals?: Armata Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Based on an average daily volume of 18,300 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's stock are sold short.
View Armata Pharmaceuticals' Short Interest.
When is Armata Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ARMP earnings forecast.

How were Armata Pharmaceuticals' earnings last quarter?: Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.55) earnings per share for the quarter. The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.68 million. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative trailing twelve-month return on equity of 280.95%.
What other stocks do shareholders of Armata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).
Who are Armata Pharmaceuticals' major shareholders?: Armata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include SeaCrest Wealth Management LLC (0.09%).
View institutional ownership trends.
How do I buy shares of Armata Pharmaceuticals?: Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ARMP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial